A practical reference on triple agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-14. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Investigational peptide material is commonly distributed as a lyophilized powder in sealed vials. The solid form appears as a white to off-white cake or powder and is hygroscopic once opened. Peptides of this size are sensitive to moisture, repeated freeze-thaw cycles, and prolonged exposure to ambient light. Handling practices therefore emphasize desiccation, minimal vial opening, and cold storage. Working aliquots are often prepared to avoid repeatedly warming the bulk container.
Solid material is generally held at -20 °C or colder, while reconstituted solutions are kept at 2-8 °C and used within a short window. Buffers that maintain a slightly acidic to neutral pH tend to improve short-term peptide stability. Repeated warming and cooling of stock solutions promotes aggregation and should be avoided. Container closures should remain intact, since adsorption to some plastics can reduce the amount of peptide in solution.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
=== Allergic conditions === Setipiprant proved to be well tolerated and reasonably effective in reducing allergen-induced airway responses in asthmatic patient clinical trials. However, the drug, while supporting the concept that DP2 contributes to asthmatic disease, did not show sufficient advantage over existing drugs and was discontinued from further development for this application.
On 7 April 2009, The Pentagon announced they spent more than $100 million in the last six months responding to and repairing damage from cyber attacks and other computer network problems. On 1 April 2009, U.S. lawmakers pushed for the appointment of a White House cyber security "czar" to dramatically escalate U.S. defenses against cyber attacks, crafting proposals that would empower the government to set and enforce security standards for private industry for the first time. On 9 February 2009, the White House announced that it will conduct a review of the country's cyber security to ensure that the Federal government of the United States cyber security initiatives are appropriately integrated, resourced and coordinated with the United States Congress and the private sector. In the wake of the 2007 cyberwar waged against Estonia, NATO established the Cooperative Cyber Defence Centre of Excellence (CCD CoE) in Tallinn, Estonia, in order to enhance the organization's cyber defence capability. The center was formally established on 14 May 2008, and it received full accreditation by NATO and attained the status of International Military Organization on 28 October 2008. Since Estonia has led international efforts to fight cybercrime, the United States Federal Bureau of Investigation says it will permanently base a computer crime expert in Estonia in 2009 to help fight international threats against computer systems.
== History == The first standardized vector, pBR220, was designed in 1977 by researchers in Herbert Boyer's lab. The plasmid contains various restriction enzyme sites and a stable antibiotic-resistance gene free from transposon activities. In 1982, Jeffrey Vieira and Joachim Messing described the development of M13mp7-derived pUC vectors that consist of a multiple cloning site and allow for more efficient sequencing and cloning using a set of universal M13 primers. Three years later, the currently popular pUC19 plasmid was engineered by the same scientists.
Sources: en.wikipedia.org
=== Genetics === Two variants (G6PD A− and G6PD Mediterranean) are the most common in human populations. G6PD A− has an occurrence of 10% of Africans and African-Americans, while G6PD Mediterranean is prevalent in the Middle East. The known distribution of the mutated allele is largely limited to people of Mediterranean origins (Spaniards, Italians, Greeks, Armenians, Sephardi Jews, and other Semitic peoples). Both variants are believed to stem from a strongly protective effect against Plasmodium falciparum and Plasmodium vivax malaria. It is particularly frequent in the Kurdish Jewish population, wherein approximately 1 in 2 males have the condition, and the same rate of females are carriers. It is also common in African American, Saudi Arabian, Sardinian males, some African populations, and Asian groups. All mutations that cause G6PD deficiency are found on the long arm of the X chromosome, on band Xq28. The G6PD gene spans some 18.5 kilobases. The following variants and mutations are well-known and described:
The U.S. National Institute of Standards and Technology investigated the collapses of the Twin Towers and 7 WTC. The investigations examined why the buildings collapsed and what fire protection measures were in place, and evaluated how fire protection systems might be improved in future construction. The investigation into the collapse of 1 WTC and 2 WTC was concluded in October 2005 and that of 7 WTC was completed in August 2008. NIST found that the fireproofing on the Twin Towers' steel infrastructures was blown off by the initial impact of the planes and that had this not occurred, the towers likely would have remained standing. A 2007 study of the north tower's collapse published by researchers at Purdue University determined that since the plane's impact had stripped off much of the structure's thermal insulation, the heat from a typical office fire would have softened and weakened the exposed girders and columns enough to initiate the collapse regardless of the number of columns cut or damaged by the impact. The director of the original investigation stated that "the towers did amazingly well. The terrorist aircraft didn't bring the buildings down; it was the fire that followed. It was proven that you could take out two-thirds of the columns in a tower and the building would still stand." The fires weakened the trusses supporting the floors, making the floors sag. The sagging floors pulled on the exterior steel columns causing the exterior columns to bow inward.
Decomposition and pressure buildup — The confinement or unintended heating of concentrated solutions can result in rapid gas evolution, leading to the risk of vessel rupture. Incompatibilities and catalysis by transition metals or organics — The presence of trace contaminants, metal ions, or organic reducing agents may accelerate decomposition or trigger radical pathways. Thermal runaway or self-accelerating decomposition — In the context of peroxide chemistry, it is crucial to consider the self-accelerating decomposition temperature (SADT) and to avoid scaling up reactions without conducting a thorough hazard assessment. Oxidizer hazards in the presence of organics — Hydrogen peroxide acts as an aggressive oxidizer. When in contact with organic substrates, solvents, or flammable materials, the risk of fire or explosion is heightened; therefore, it is essential to ensure that oxidizer storage is kept separate from reducing materials. High-concentration hydrogen peroxide streams, typically above 40%, should be considered hazardous due to concentrated hydrogen peroxide's meeting the definition of a DOT oxidizer according to U.S. regulations if released into the environment. The EPA Reportable Quantity (RQ) for D001 hazardous wastes is 100 pounds (45 kg), or approximately 10 US gallons (38 L), of concentrated hydrogen peroxide.
Sources: en.wikipedia.org
Yohimbine selectively blocks the pre-synaptic α2-adrenergic receptors. Blockade of post-synaptic α2-adrenergic receptors causes only minor corpus cavernosum smooth muscle relaxation, due to the fact that the majority of adrenoceptors in the corpus cavernosum are of the α1 type. Blockade of pre-synaptic α2-adrenergic receptors facilitates the release of several neurotransmitters in the central and peripheral nervous system—thus in the corpus cavernosum—such as nitric oxide and norepinephrine. Whereas nitric oxide released in the corpus cavernosum is the major vasodilator contributing to the erectile process, norepinephrine is the major vasoconstrictor through stimulation of α1-adrenergic receptors on the corpus cavernosum smooth muscle. Under physiologic conditions, however, nitric oxide attenuates norepinephrine vasoconstriction. Yohimbine binds to the a2 adrenergic receptor at a ratio of 40:1 and is the only a2 adrenergic receptor antagonist with no imidazoline receptor activity.
==== Resignation ==== Cabinet met on the morning of Thursday 9 January, with Thatcher already having agreed her position with close colleagues at Chequers that weekend, and arranged that Scottish Secretary George Younger should take over as Defence Secretary if Heseltine resigned. Westland was first on the agenda, and Heseltine and Brittan were permitted to put their cases. Heseltine had won the moral high ground over the leaking saga, but Lawson recorded that he seemed obsessive at Cabinet and attracted little sympathy. Thatcher then reiterated her position, which had already been endorsed by the Cabinet, that Westland's future was a matter for Westland to decide, and announced that on grounds of Collective responsibility all answers to questions about Westland must in be cleared through the Cabinet Office. In response to a question by Nicholas Ridley (a friend of Heseltine) she confirmed that this also applied to statements which had already been made. Following further questions from Heseltine, and another summing up by Thatcher, Heseltine protested that there had been no collective responsibility, gathered up his papers and left the Cabinet Room. Eyewitness accounts differ as to his exact words, or even whether he explicitly resigned. By one account he declared, "I can no longer be a member of this Cabinet." Having allegedly paid a quick visit to the lavatory to straighten his hair and his Guards tie, Heseltine announced his resignation to the waiting press outside Number Ten, the first Cabinet minister to resign from a Cabinet meeting since Joseph Chamberlain in 1886.
2017, D. A. Belcher, U. Banerjee, C. M. Baehr, K. E. Richardson, P. Cabrales, F. Berthiaume, A. F. Palmer, “Mixtures of tense and relaxed state polymerized human hemoglobin regulate oxygen affinity and tissue construct oxygenation,” PLoS One Oct 11;12(10):e0185988. 2020, L. Diaz-Starokozheva, D. Das, X. Gu, J. T. Moore, L. R. Lemmerman, I. Valerio, H. M. Powell, N. Higuita-Castro, M. R. Go, A. F. Palmer, D. Gallego-Perez, “Early intervention on ischemic tissue with oxygen nanocarriers enables successful implementation of restorative cell therapies,” Cellular and Molecular Bioengineering May 29;13(5):435-446. 2020, D. A. Belcher, A. Lucas, P. Cabrales, A. F. Palmer, “Tumor vascular status controls oxygen delivery facilitated by infused polymerized hemoglobins with varying oxygen affinity,” PLOS Computational Biology Aug 20;16(8):e1008157. Plasma substitutes Palmer's lab demonstrated that human serum albumin (PolyHSA) is able to resuscitate animals from hemorrhagic shock, endotoxemia, sepsis, and ischemia reperfusion injury. Supporting publications:
In a clandestine setting, DMT is not typically synthesized due to the lack of availability of the starting materials, namely tryptamine and oxalyl chloride. Instead, it is more often extracted from plant-sources using a nonpolar hydrocarbon solvent such as naphtha or heptane, and a base such as sodium hydroxide. Alternatively, an acid-base extraction is sometimes used instead. A variety of plants contain DMT at sufficient levels for being viable sources such as Mimosa tenuiflora, Acacia acuminata, Acacia confusa, Acacia maidenii, Arundo donax, 'Diplopterys cabrerana, Psychotria viridis. The chemicals involved in the extraction are commonly available. The plant-material may be illegal to procure in some countries. The end-product (DMT) is illegal in most countries.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
Solid powder is held frozen at -20 °C or below in a desiccated container. Reconstituted solutions are refrigerated and used within a limited period.